Document is current
Any future updates will be listed below
-
Authors
Couturaud, F. https://orcid.org/0000-0002-1855-8032
Mahé, I.
Schmidt, J.
Gleize, J-C.
Lafon, T.
Saighi, A.
Sedjelmaci, F.
Bertoletti, L.
Mismetti, P.
- License Information
-
More Information
Article History
Received: 22 February 2022
Accepted: 23 April 2023
First Online: 10 June 2023
Declarations
:
: This research involves human data and has been performed in accordance with the Declaration of Helsinki and International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP). This study used secondary data, there was a public interest in assessing cancer-associated venous thromboembolism in France in a real-life study, and the protection of patients’ rights and freedom were guaranteed. In addition, this is a retrospective study based on an anonymized database which had no influence on patient care. Hence, the study fell under the MR006 framework of the French data protection agency (Commission Nationale de l'Informatique et des Libertés; CNIL). According to national regulations and the MR006 framework, ethics approval and patient informed consent were unnecessary.
: Not applicable.
: Dr Couturaud reports grants from Pfizer and Bayer, personal fees and other from Bayer, other from Boehringer, grants, personal fees and other from BMS, personal fees and other from AstraZeneca, other from GSK, personal fees from Leo pharma, other from Actelion, outside the submitted work. Dr Schmidt declare no conflict of interest. Dr. Mahé reports personal fees from Pfizer, during the conduct of the study; grants, personal fees and non-financial support from LEO Pharma, personal fees and non-financial support from Bayer, grants, personal fees and non-financial support from BMS/Pfizer, grants from Stago and BMS-Pfizer, outside the submitted work. Dr. Mismetti reports personal fees from Bayer Healthcare, personal fees from BMS/PFIZER, personal fees from Boehringer Ingelheim, outside the submitted work. Dr Bertoletti reports personal fees from SANOFI, personal fees and non-financial support from LEO-PHARMA, personal fees and non-financial support from ASPEN, personal fees from BAYER, personal fees and non-financial support from BMS/Pfizer, grants, personal fees and non-financial support from MSD, during the conduct of the study. Dr. Saighi and Dr. Sedjelmaci are PFIZER employee. Dr. Gleize and Mr. Lafon report employment by HEVA, during the conduct of the study.
